Group 1 - The core viewpoint is that multiple institutions maintain a positive rating for Ascentage Pharma-B (06855.HK), with 100% of market opinions suggesting buy or hold positions [1] - CICC's report from December 2025 highlights that the global Phase III study POLARIS-1 for Olverembatin (耐立克) has received approval from both the FDA and EMA, and the clinical data for APG-2575 (利生妥) is impressive, maintaining a target price of HKD 89 [1] Group 2 - Over the past 7 days (as of February 20, 2026), Ascentage Pharma-B's stock price fluctuated, closing at HKD 47.46 on February 20, a slight decrease of 0.08% from HKD 46.68 on February 16, with a trading range of 4.55% [2] - During the same period, the US stock (AAPG.OQ) closed at USD 24.34, reflecting a cumulative increase of 2.18% [2] - Capital flow data indicates a net inflow of HKD 993,600 into the Hong Kong stock market on February 20, with overall trading activity being light [2]
亚盛医药-B获机构积极评级，股价微跌资金流入